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Background. The Global Pertussis Initiative, an expert scientific forum, was established to address the ongoing
problems associated with pertussis disease worldwide.
Methods. The group analyzed pertussis disease trends, developed recommendations to improve disease control
through expanded vaccination strategies, and proposed solutions to barriers to implementation and support of
research activities.
Results. Bordetella pertussis infection is endemic and continues to be a serious problem among unvaccinated
or incompletely vaccinated infants. In addition, the reported incidence of pertussis disease is increasing in ado-
lescents and adults, who not only experience a considerable health burden themselves but also infect vulnerable
infants.
Conclusions. Current vaccination strategies need to be reinforced. Expanded vaccination should include adding
booster doses to existing childhood schedules (preschool or adolescent) and booster doses for those specific adult
subgroups that have the highest risk of transmitting B. pertussis infection to infants (i.e., new parents, other contacts
of newborns, and health care workers). More epidemiological studies and studies of disease transmission and the
cost-effectiveness of vaccination would be valuable, and surveillance, diagnostic improvements, and educational
campaigns are needed for implementation. However, as a prelude to universal adult vaccination, immediate universal
adolescent vaccination should be instituted in countries in which it is economically feasible.
For more than 40 years, whole-cell pertussis (wP) vac-
cination of infants and toddlers has been highly ef-
fective, preventing ∼760,000 deaths annually world-
wide [1]. Nevertheless, there are an estimated 50
million cases of pertussis disease and 300,000 pertus-
sis-related deaths every year globally, mostly among
infants who are too young to have completed the pri-
mary vaccination series [2].
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In response to the ongoing problem of pertussis, an
international collaboration of multidisciplinary ex-
perts—the Global Pertussis Initiative (GPI)—was es-
tablished in 2001 to examine the rationale for vacci-
nation beyond childhood [3, 4] and to evaluate specific
strategies, make recommendations for their implemen-
tation, and identify research needs to support their in-
troduction. This article summarizes the findings and
recommendations of the GPI.
The views, opinions, assertions, and findings contained herein are those of the
authors and should not be construed as official policies or decisions of the authors’
employers or any other organization that the authors represent, unless designated
by other documentation. The recommendations on the use of vaccines for uses
not approved by the Food and Drug Administration (FDA) do not represent the
official views of the FDA or of any of the federal agencies whose scientists
participated in the initiative.
a Members of the study group are listed at the end of the text.
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METHODS
The GPI was conducted in 3 stages: (1) international epide-
miology, diagnosis, health and economic burden, and preven-
tion and treatment of pertussis were assessed; (2) immunization
strategies to address the problems identified were evaluated and
prioritized; and (3) solutions to potential barriers to strategy
implementation were identified. Exchange of data, knowledge,
experience, and opinion was facilitated by discussion, debate,
and voting through the use of a closed, interactive Web site,
teleconferences, and a roundtable meeting.
PROBLEMS POSED BY PERTUSSIS
Bordetella pertussis endemicity. B. pertussis infection re-
mains endemic, even in countries with a sustained high rate
of vaccination coverage. Among the countries participating in
the GPI, reported incidences ranged from 0.1 to 200 cases per
100,000 population [5–9].
Pertussis in adolescents and adults. Although pertussis is
not generally perceived to be a serious problem beyond child-
hood, adolescents and adults experience a significant health
burden from the disease [10]. Clinical manifestations are often
atypical [11]. However, 21%–86% of adults have typical symp-
toms of paroxysmal cough, whoop, and posttussive vomiting,
which can be severe [12]. Studies indicate that 12%–32% of
adolescents and adults with a coughing illness lasting 1–2 weeks
or longer are infected with B. pertussis [13]. Most (80%) of the
adolescents and adults with pertussis disease have a cough last-
ing 21 days [14], and many (27%) are still coughing at 90
days after onset [12, 15].
Pertussis-related complications, some of which may be se-
rious [16], also occur fairly frequently in adolescents and
adults [17]. Although hospitalization due to pertussis disease
is most frequent among infants, it is not infrequent among
adolescents and adults [18]. However, mortality is low among
patients 10 years of age who are hospitalized with cases of
pertussis [19, 20].
Pertussis disease is increasing among adolescents and adults
[15, 21]. This may be because of multiple factors, including
waning vaccine-induced immunity and increased recognition,
diagnosis, and reporting of pertussis disease. However, it is clear
that adolescents and adults are commonly and regularly in-
fected with B. pertussis and, therefore, are potentially a major
source of pediatric infection [11, 22].
There is widespread agreement that parents are a common
source of B. pertussis infection for infants [23, 24]. Grandpar-
ents, aunts, and uncles are also potential sources of infection
[25, 26]. Although data reported from Germany have indicated
similar levels of antipertussis toxin and other pertussis-related
antibodies in pediatraic health care workers and non–health
care workers [27], the increased risk of health care workers
coming into contact with unprotected newborns makes this
adult subgroup a focus when considering whom to vaccinate
[28]. Adolescents are also an important reservoir of infection
for infants and other household members [23].
Pertussis in neonates and infants. Infants, particularly
those who are not fully vaccinated, continue to experience the
greatest pertussis disease burden [2]. In Finland, a 5-fold in-
crease in the reported incidence of pertussis disease among
those !1 year old occurred between 1995 and 1999, and in the
United States, the mean annual incidence among infants 4
months old increased from 63.4 cases per 100,000 population
in the 1980s to 88.7 cases per 100,000 population in the 1990s;
the mean annual incidence of pertussis disease among infants
aged2 months increased by 49%, from 72.1 cases per 100,000
population in the 1980s to 107.3 cases per 100,000 population
in the 1990s [29].
Mortality due to pertussis disease is highest among infants
[30]. Moreover, the number of infant deaths due to pertussis
may be underreported because of misdiagnosis of pertussis as
other respiratory illnesses or sudden infant death syndrome
[31–34].
Economic burden of pertussis. The economic burden of
pertussis is significant. A US study estimated the direct costs
of pertussis disease at $2822 (i2209) for infants, $308 (i241)
for children, $254 (i199) for adolescents, and $181 (i142) for
adults [35]. For infants, hospitalizations accounted for two-
thirds of medical costs [35]. German data on children aged6
years estimated the direct costs of an uncomplicated case of
pertussis at ∼i110 (∼$141). If a case involved hospitalization,
pneumonia, or encephalopathy, the costs were i1700 ($2171),
i3940 ($5033), and i5170 ($6604), respectively [36]. For chil-
dren, adolescents, and adults, most direct costs are incurred
through physician office visits, but antibiotic treatment and
hospitalization also contribute to the expense [12]. The indirect
costs of pertussis disease also appear to be substantial, partic-
ularly among adults, for whom personal illness or child care
responsibilities frequently result in absenteeism or reduced pro-
ductivity [12].
Problems with pertussis diagnosis and surveillance. Re-
ported cases of pertussis disease are estimated to be 1%–36%
of the true number of cases [8, 37]. Underrecognition, under-
reporting, and misdiagnosis are widespread, and they are a
particular problem with adolescent and adult disease.
Intercountry comparisons and global evaluations are dif-
ficult to perform, because countries use different pertussis
disease case definitions, diagnostic techniques, surveillance
methods, and reporting regulations [38, 39]. Laboratory di-
agnosis of B. pertussis infection is also problematic. Culture
and PCR are difficult to perform and of low sensitivity if the
patient’s disease has progressed beyond the catarrhal phase
of the illness. Although there are numerous PCR and antibody
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Table 1. Immunization strategies assessed by the Global Pertussis Initiative.
Immunization strategy Potential schedule Primary objectives Secondary objectives
Universal adult immunization All adults aged 18 years at reg-
ular intervals (possibly coincid-
ing with diphtheria, tetanus,
and polioa boosters)
Reduce morbidity in adults;
develop herd immunity
Reduce Bordetella pertussis
transmission to young infants
Selective immunization of new
mothers, family, and close
contacts of newborns
Either prenatally during the third
trimester or perinatally before
the newborn reaches 4 weeks
of age
Reduce disease transmission to
young infants
Reduce morbidity in adults,
especially young adults
Selective immunization of health
care workers
On entry into the profession (re-
gardless of diphtheria, tetanus,
and polioa vaccination status),
followed by administration of
booster doses, as appropriate
Reduce disease transmission to
susceptible patients (including
young infants)
Reduce morbidity in health care
workers
Selective immunization of child
care workers
On entry into the profession (re-
gardless of diphtheria, tetanus,
and polioa vaccination status),
followed by booster doses, as
appropriate
Reduce disease transmission to
young infants
Reduce morbidity in child care
workers
Universal adolescent
immunization
Age 11–12 years (depending on
the recommended age for ad-
ministration of diphtheria, teta-
nus, and polioa booster doses),
with catch-up until age 18
years
Reduce morbidity in adolescents
and young adults; develop
herd immunity
Reduce disease transmission to
young infants
Universal preschool booster
doses at 4–6 years of age
All preschool or early school
children 4–6 years of age
Reduce morbidity in school-aged
children; develop herd
immunity
Reduce disease transmission to
young infants
Reinforce and/or improve current
infant and toddler immuniza-
tion strategies
As per current recommenda-
tions, which vary from country
to country
Reduce morbidity and mortality
in infants, toddlers, and
children
Reduce overall circulation of
B. pertussis
a Polio booster doses are administered to children 15 years old in some, but not all, countries.
assays available, PCR assays must be standardized, and ex-
perienced individuals are needed to accurately interpret per-
tussis antibody concentrations.
WANING IMMUNITY AND THE NEED TO
EXPAND EXISTING VACCINATION STRATEGIES
The key factor underlying the continuing endemicity of B. per-
tussis infection in countries with high rates of vaccination is
that both vaccine-induced and naturally acquired immunity
wane without boosting. Although the precise time frame re-
mains unresolved, immunity provided by wP vaccines appears
to persist for at least 3–5 years and then to progressively decline
6–10 years after vaccination [40]. The limited data on acellular
pertussis (aP) vaccines suggest that, in most cases, protective
immunity persists for 6 years after primary vaccination with
3 or 4 doses [41–43]. A study conducted in Senegal [44] has
shown that even partially vaccinated patients with breakthrough
cases of pertussis are less contagious than unvaccinated patients
with cases of pertussis.
VACCINATION STRATEGIES: GENERAL
CONSIDERATIONS
The GPI defined and evaluated 7 strategies to complement or
improve current childhood vaccination schedules (table 1). Sev-
eral countries already have a preschool pertussis booster. Aus-
tralia, Austria, Canada, France, Germany, and Switzerland have
an adolescent booster. In Switzerland, catch-up vaccination for
adolescents who have missed the fourth and/or fifth dose at
preschool age is recommended. Recently, Austria and Canada
recommended routine aP boosters in adults.
Universal adult vaccination. In countries where low-dose
diphtheria and tetanus (dT) or dT–inactivated polio vaccine
(dT-IPV) boosters are already recommended for adults every
10 years, a switch to a dTaP vaccine or dTaP-IPV would be
relatively simple and inexpensive. However, a massive educa-
tional effort would be required to maximize uptake. The high-
est coverage possible would be necessary for optimal levels of
protection and herd immunity; an epidemiological model
suggested that a coverage of 185% would be needed to ef-
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fectively reduce the number of cases of infant pertussis [45].
Where appropriate dT vaccine or dT-IPV programs do not
exist, a new delivery infrastructure would be needed. In the
absence of research indicating otherwise, vaccination every 10
years is a reasonable frequency to recommend for universal
adult vaccination.
The vaccines of choice would be acellular vaccines (com-
bination dTaP vaccine or dTaP-IPV, or stand-alone aP vaccine),
which have been shown to have good immunogenicity, efficacy,
and safety profiles in adolescents and adults [46]. Protection
of ∼80% has been reported [47], but further efficacy data are
needed. Suitable dTaP vaccines and dTaP-IPVs are now licensed
for adults and adolescents in many countries, including Aus-
tralia, Canada, and most European countries. To avoid gaps in
protection for individuals who have recently received a dT or
dT-IPV booster dose, a stand-alone aP vaccine should be made
available to complement the current combined vaccines. Be-
cause adolescents are a significant reservoir of B. pertussis [48],
universal adult vaccination would have to be accompanied by
universal adolescent vaccination.
Universal adolescent vaccination. Because vaccine-
induced immunity to B. pertussis infection is likely to have
decreased significantly by adolescence, and because the reported
incidence of B. pertussis infection is increasing in this group
[49], an adolescent booster dose will prolong immunity and
reduce disease prevalence (and thereby transmission) in this
age group, indirectly reducing transmission to vulnerable in-
fants. However, in the absence of universal adult vaccination,
adolescent vaccination will not sufficiently control B. pertussis
circulation and transmission to infants.
In many countries, dT or dT-IPV booster doses are given in
early adolescence (generally before 16 years of age) through
school-based programs, so switching to a dTaP vaccine would
be simple. All individuals !18 years of age (or younger than
the nationally defined upper age range for adolescence) who
have already received a dT or dT-IPV booster dose could be
given a stand-alone aP vaccine, if available, to ensure adequate
protection. For countries not operating school vaccination pro-
grams, an extensive education program will be required to en-
courage uptake.
Universal preschool booster doses at 4–6 years of age.
Randomized trials have reported increased antibody titers after
receipt of pertussis booster doses at 4–7 years of age [50, 51],
and health-economic models have indicated potential health
benefits and cost-effectiveness with this strategy [52, 53]. After
the introduction of a booster dose for 4–6-year-old children,
the disease burden in US preschool and school children de-
creased [7].
With administration of a booster dose at 4–6 years of age,
it is expected that immunity will be extended into adolescence.
The possibility of moving administration of the adolescent
booster dose from early adolescence to mid-adolescence could
be explored.
Administration of a pertussis booster dose at 4–6 years of
age is already included in the vaccination schedules of some
countries. In others, this strategy would require the introduc-
tion of a fourth or fifth booster dose for this age group.
Selective vaccination of new mothers, family, and close con-
tacts of newborns. Two main vaccination schedules were con-
sidered for this strategy: vaccination of mothers prenatally (dur-
ing the third trimester) and vaccination of mothers, fathers,
family members, and other close contacts perinatally (before
the infant reaches 4 weeks of age). Maternal vaccination during
pregnancy might reduce transmission of B. pertussis infection
from mother to newborn and have the advantage of transferring
antibodies to the infant via the placenta. However, studies of
prenatal vaccination using wP vaccines have been inconclusive
in this regard [54].
Given the general public concern about vaccinations in preg-
nancy, postnatal vaccination of mothers may be a more ac-
ceptable option than prenatal vaccination. Other family mem-
bers and close contacts would also be vaccinated, preferably
during the prenatal period but, failing this, within the first 4
weeks of the newborn’s life. This strategy would be easier to
implement than universal adult vaccination, because mothers
are easy to access via their contact with health care services and
are motivated to protect their infants. Access to other family
members and other potential close contacts would be more
difficult to achieve, but education on the potential risks of
transmitting B. pertussis to a young infant should motivate them
to be vaccinated.
Selective vaccination of child care and health care workers.
In many countries, few infants !6 months of age attend day
care, so vaccinating child care workers may not contribute sig-
nificantly to reducing infant morbidity and mortality. However,
infants and children who are exposed to child care workers
infected with B. pertussis are at particular risk of infection be-
cause of the greater chance of prolonged and close contact.
Preventing and diagnosing B. pertussis infection among health
care workers is also important.
A European Union directive specifies that all persons at oc-
cupational risk from infectious agents should be offered vac-
cination at the employer’s expense if an effective vaccine is
available [55]. Currently, Austria and Germany are the only
countries implementing this directive. Experience with influ-
enza vaccination suggests that some health care workers are
reluctant to be vaccinated [56], but education of this target
group should maximize compliance.
Selective vaccination of health care and child care workers
would require vaccination on entry into the profession and
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Table 2. Research needs identified by the Global Pertussis Initiative to facilitate implementation
of expanded immunization schedules.
Epidemiology and transmission
Information on the correlation between seropositivity and disease presentation
The influence of vaccination policy and natural boosting on the age-related incidence of symptom-
atic versus asymptomatic infection
Monitoring of emerging antigenic variants that might compromise vaccine efficacy
Further studies to establish whether there is a reduced opportunity for natural boosting among
populations where uptake of childhood pertussis vaccination is high
Surveillance and diagnosis
Enhanced surveillance methods are needed to collect accurate epidemiological and vaccine
coverage data
Clinical case definitions of pertussis disease should be standardized, particularly for mild disease
Rapid, reliable, widely available, easy-to-use, and inexpensive laboratory diagnostic techniques are
needed, as are the standardization and increased use of PCR and antibody testing techniques
Vaccines
Further data on the effectiveness and reactogenicity of adolescent/adult acellular pertussis
vaccines
Determine the duration of vaccine-induced immunity
Maternal and neonatal vaccination
Data on the safety of pertussis vaccines administered during the last trimester of pregnancy
Further research on whether high titers of antibodies induced in mothers before delivery confer
protection on the infant, and also whether high titers of antibodies, if passed to the infant,
interfere with active immunization in infancy
Cost-effectiveness: cost-effectiveness studies of recommended strategies
Enhancing program implementation
Simple, effective educational campaigns are needed for health care professionals and the public
Political will needs to be raised
All countries must ensure that they have effective vaccines, delivery infrastructures, and
appropriate diagnostic techniques and surveillance systems
Additional research into public perceptions and understanding of pertussis disease and
vaccination in adults
regular booster doses throughout employment. Health care
workers are easy to access, although the timing of vaccination
would depend on their vaccination history before starting work.
A pragmatic approach would be to combine pertussis vacci-
nation every 10 years with dT or dT-IPV booster doses.
Reinforce and/or improve current infant and toddler vac-
cination strategies. To ensure that current infant and toddler
vaccination strategies are reinforced and/or improved, public
health education, particularly for parents, is important. Efforts
are needed to ensure that vaccinations are not missed or de-
layed, because study data indicate that even a single vaccination
may protect against severe disease and hospitalization [43, 57].
STRATEGY RECOMMENDATIONS BY THE GPI
GPI participants agreed that any changes in pertussis vacci-
nation strategies should be underpinned by improved vaccine
coverage of infants and toddlers, particularly in impoverished
and deprived populations, for whom coverage rates may be
poor. However, it was universally acknowledged that, even if
100% coverage of infants and children was achieved, infants
too young to be vaccinated would still be vulnerable. Booster
vaccination of groups who are currently beyond the recom-
mended age range is therefore needed.
North America. For North America, it was agreed that the
overall objective should be to develop lifelong immunity to B.
pertussis infection. This would best be achieved by introducing
universal adolescent and adult vaccination.
All North American participants agreed that adolescent vac-
cination should be introduced. Although adult vaccination is
the logical eventual goal, the group was divided on whether
there are sufficient data to support its introduction. More re-
search is needed, particularly on the duration of immunity
conferred by aP vaccines in adults. A minority in the group
strongly believed that universal adult vaccination is justified by
the available data and urged its immediate introduction. The
remainder proposed a step-wise approach and recommended
initially focusing on vaccination of all adolescents, supple-
mented by vaccination of specific adult subgroups (including,
but not limited to, young adults and new parents, close contacts
of newborns, health care workers, and child care workers).
Although this would be unlikely to have any significant overall
effect on extending herd immunity or reducing pertussis cir-
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culation, the approach acknowledges the likely logistical and
economic barriers to introducing a program of regular adult
pertussis booster doses.
Europe. Three strategies were proposed for the European
region. First, adherence to current national schedules should
be reinforced through improved education for the public and
health care workers. Second, the best pan-European strategy
would be for most countries to add a dose to the existing
schedule by introducing universal preschool or adolescent
booster doses. Selective vaccination of health care workers
should be implemented in all countries, in line with the Eu-
ropean Community directive [55].
International. Because of a wide spectrum of epidemio-
logical conditions, vaccination requirements, and health care
resources in the international region, consistent proposals for
all participating countries were not possible. Nevertheless, pri-
mary objectives were deemed similar in Argentina, Australia,
and Japan—to reduce morbidity in adolescents and young
adults and to develop herd immunity. The following strategies
were considered important in meeting these objectives.
• For Australia, Argentina, and Japan, universal vaccination
of adolescents was recommended. Australia has recently re-
moved the 18-month DTaP vaccine dose from the vacci-
nation schedule and replaced the dT vaccine given to ad-
olescents 15–19 years old with a dTaP vaccine.
• For Australia, selective vaccination of new mothers, family,
and close contacts of newborns and selective vaccination of
health care workers was recommended.
• For Japan, a fourth booster dose for all preschool children
(which is already given in Australia and Argentina) was
recommended.
Brazil is unlikely to expand pertussis vaccination without
further data on health benefits and cost-effectiveness because
of a current focus on controlling tuberculosis and malaria.
ADDITIONAL RESEARCH AND
IMPLEMENTATION REQUIREMENTS
The introduction and refinement of expanded vaccination strat-
egies should be supported by a range of research efforts and
common measures (table 2).
SUMMARY
Although pertussis epidemiology and health care priorities vary
worldwide, all countries should ensure the highest possible cov-
erage rates among infants and children and should consider
expanding existing vaccination strategies with the goals of re-
ducing transmission to young infants, developing herd im-
munity, and reducing morbidity in children, adolescents, and
adults. Complete protection against pertussis, particularly
against serious disease in young infants, will require lifelong
universal vaccination. However, recognizing the unfeasibility of
immediate implementation of this approach, most GPI mem-
bers recommended that countries with high levels of infant
vaccination first consider administration of booster doses to
4–6-year-old children at school entry, to adolescents, and to
specific adult groups (such as young adults and new parents,
other contacts of newborns, and child care and health care
workers), with concurrent accumulation of data on the safety
and effectiveness of those programs. Universal adult vaccination
is the logical goal in countries in which it is economically
feasible.
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